US 12,760,102 B2Granted

Antibodies specific to CTLA-4 and uses thereof

AssigneesTikcro Technologies Ltd., Yeda Research and Development Co. Ltd.

InventorsAmi Navon, Aviv Boim, Ariel Stanhill, Leehee Weinberger, Yuval Avnir

Life of this patent

Estimating the term…

Abstract

Disclosed herein are anti-CTLA-4 antibodies possessing superior binding and biological activities relative to ipibmumab and tremelimumab, pharmaceutical compositions comprising such. Also provided herein are therapeutic and diagnostic applications of such anti-CTLA-4 antibodies.

Claims22

Dependent claims

A monoclonal antibody binding to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),

(a) wherein the antibody comprises a heavy chain variable domain (VH), which comprises (i) a heavy chain complementary determining region 1 (HC CDR1) set forth as GDYYWG (SEQ ID NO:
15);
(ii) a heavy chain complementary determining region 2 (HC CDR2) set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) a heavy chain complementary determining region 3 (HC CDR3) set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a light chain variable domain (VL), which comprises (i) a light chain complementary determining region 1 (LC CDR1) set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) a light chain complementary determining region 2 (LC CDR2) set forth as GASTRAT (SEQ ID NO:
22);
and (iii) a light chain complementary determining region 3 (LC CDR3) set forth as QQYNNWPPLT (SEQ ID NO:
8);
(b) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWN (SEQ ID NO:
28);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(c) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHDGYTYYNPSLKS (SEQ ID NO:
31);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(d) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSAYTYYNPSLKS (SEQ ID NO:
32);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(e) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSVKS (SEQ ID NO:
33);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(f) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFAY (SEQ ID NO:
34);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(g) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDI (SEQ ID NO:
35);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(h) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSISSNLA (SEQ ID NO:
49);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(i) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as AASTRAT (SEQ ID NO:
53);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(j) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GATTRAT (SEQ ID NO:
54);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
or
(k) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASSRAT (SEQ ID NO:
55);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8).

130 more elements

A genetically engineered immune cell, which expresses a chimeric antigen receptor comprising an extracellular domain and at least one cytoplasmic signaling domain, wherein the extracellular domain is a single chain variable fragment (scFv) of a CTLA-4-binding antibody,

(a) wherein the scFv comprises a heavy chain variable domain (VH), which comprises (i) a heavy chain complementary determining region 1 (HC CDR1) set forth as GDYYWG (SEQ ID NO:
15);
(ii) a heavy chain complementary determining region 2 (HC CDR2) set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) a heavy chain complementary determining region 3 (HC CDR3) set forth as DSGWYVIAFDY (SEQ ID NO:
17) and wherein the scFv comprises a light chain variable domain (VL), which comprises (i) a light chain complementary determining region 1 (LC CDR1) set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) a light chain complementary determining region 2 (LC CDR2) set forth as GASTRAT (SEQ ID NO:
22);
and (iii) a light chain complementary determining region 3 (LC CDR3) set forth as QQYNNWPPLT (SEQ ID NO:
8);
(b) wherein the scFv comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWN (SEQ ID NO:
28);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the scFv comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(c) wherein the scFv comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHDGYTYYNPSLKS (SEQ ID NO:
31);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the scFv comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(d) wherein the scFv comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSAYTYYNPSLKS (SEQ ID NO:
32);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the scFv comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(e) wherein the scFv comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSVKS (SEQ ID NO:
33);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the scFv comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(f) wherein the scFv comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFAY (SEQ ID NO:
34);
and wherein the scFv comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(g) wherein the scFv comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDI (SEQ ID NO:
35);
and wherein the scFv comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(h) wherein the scFv comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the scFv comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSISSNLA (SEQ ID NO:
49);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(i) wherein the scFv comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the scFv comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as AASTRAT (SEQ ID NO:
53);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(j) wherein the scFv comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the scFv comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GATTRAT (SEQ ID NO:
54);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
or
(k) wherein the scFv comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the scFv comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASSRAT (SEQ ID NO:
55);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8).

129 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/278,261Filed 20 Sep 2019 · us provisional application
Priority: 20 Sep 2018
Published: US 2021/0355220 A118 Nov 2021
Granted: 13 Oct 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification7 codes

C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies
C07K 2317/34
Characterized by aspects of specificity or valency: identification of a linear epitope shorter than 20 amino acid residues or of a conformational…
C07K 2317/565
Variable region, i.e. VH and/or VL: complementarity determining region [CDR]

Family

Application62/734,078Us provisional application · filed 20 Sep 2018
Application62/825,629Us provisional application · filed 28 Mar 2019
US 2021/0355220 A1Pre-grant publication · published 18 Nov 2021
US 2023/0132385 A9Pre-grant publication · published 27 Apr 2023
US 12,760,102 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

A monoclonal antibody binding to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),

(a) wherein the antibody comprises a heavy chain variable domain (VH), which comprises (i) a heavy chain complementary determining region 1 (HC CDR1) set forth as GDYYWG (SEQ ID NO:
15);
(ii) a heavy chain complementary determining region 2 (HC CDR2) set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) a heavy chain complementary determining region 3 (HC CDR3) set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a light chain variable domain (VL), which comprises (i) a light chain complementary determining region 1 (LC CDR1) set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) a light chain complementary determining region 2 (LC CDR2) set forth as GASTRAT (SEQ ID NO:
22);
and (iii) a light chain complementary determining region 3 (LC CDR3) set forth as QQYNNWPPLT (SEQ ID NO:
8);
(b) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWN (SEQ ID NO:
28);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(c) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHDGYTYYNPSLKS (SEQ ID NO:
31);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(d) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSAYTYYNPSLKS (SEQ ID NO:
32);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(e) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSVKS (SEQ ID NO:
33);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(f) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFAY (SEQ ID NO:
34);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(g) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDI (SEQ ID NO:
35);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(h) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSISSNLA (SEQ ID NO:
49);
(ii) an LC CDR2 set forth as GASTRAT (SEQ ID NO:
22);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(i) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as AASTRAT (SEQ ID NO:
53);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
(j) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GATTRAT (SEQ ID NO:
54);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8);
or
(k) wherein the antibody comprises a VH, which comprises (i) an HC CDR1 set forth as GDYYWG (SEQ ID NO:
15);
(ii) an HC CDR2 set forth as SIYHSGYTYYNPSLKS (SEQ ID NO:
16);
and (iii) an HC CDR3 set forth as DSGWYVIAFDY (SEQ ID NO:
17);
and wherein the antibody comprises a VL, which comprises (i) an LC CDR1 set forth as RASQSVSSNLA (SEQ ID NO:
21);
(ii) an LC CDR2 set forth as GASSRAT (SEQ ID NO:
55);
and (iii) an LC CDR3 set forth as QQYNNWPPLT (SEQ ID NO:
8).

130 more elements

Facts

Application

17/278,261Filed 20 Sep 2019 · us provisional application

Priority

20 Sep 2018

Published

US 2021/0355220 A118 Nov 2021

Granted

13 Oct 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification7 codes

C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies
C07K 2317/34
Characterized by aspects of specificity or valency: identification of a linear epitope shorter than 20 amino acid residues or of a conformational…
C07K 2317/565
Variable region, i.e. VH and/or VL: complementarity determining region [CDR]

Family

Application62/734,078Us provisional application · filed 20 Sep 2018

Application62/825,629Us provisional application · filed 28 Mar 2019

US 2021/0355220 A1Pre-grant publication · published 18 Nov 2021

US 2023/0132385 A9Pre-grant publication · published 27 Apr 2023

US 12,760,102 B2This patent

From the US filing history. Foreign family members aren’t listed.